Immunotherapy of SV40 induced tumours in mice: a model for vaccine development.
Various vaccination strategies were compared for their ability to elicit antigen-specific tumour immunity, using the SV40-BALB/c murine tumour system. Specifically, mice were injected with baculovirus-derived recombinant SV40 Tag (rTag), synthetic peptides corresponding to B cell epitopes on SV40 Tag or a plasmid DNA construct encoding the gene for SV40 Tag. In vivo tumour immunity was determined by a lethal tumour challenge with syngeneic SV40-transformed tumour cells. SV40 Tag-specific antibody titres were induced in mice immunized with rTag or Tag synthetic peptides. Partial tumour protection was observed in mice that were immunized with SV40 Tag peptides, where as complete tumour immunity was observed in mice immunized with rTag. Although protective tumour immunity was also observed in mice immunized with DNA, negligible levels of antibodies to SV40 Tag were detected. Examination of the cytotoxic T lymphocyte (CTL) activity in mice injected with the SV40 Tag-DNA construct revealed Tag-specific lysis of syngeneic SV40-transformed tumour cells. Conversely, little to no CTL activity was detected in mice immunized with rTag. However, antigen-specific antibodies from rTag immunized mice were capable of mediating antibody-dependent cell-mediated cytotoxicity against SV40-transformed cells. These data indicate that the immune mechanisms elicited for protection against SV40 induced tumours in mice appeared to be dependent on the vaccination strategy employed and included both humoral and cell-mediated immune responses.
Surgery Department and the Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201-1379, USA.
R K
RK
Bright
M H
MH
Shearer
H I
HI
Pass
R C
RC
Kennedy
D000818:Animals; D000952:Antigens, Polyomavirus Transforming / Q000235:genetics / Q000276:immunology; D018985:Epitopes, B-Lymphocyte / Q000276:immunology; D005260:Female; D051379:Mice; D008807:Mice, Inbred BALB C; D030361:Papillomavirus Infections / Q000628:therapy*; D011994:Recombinant Proteins / Q000276:immunology; D013539:Simian virus 40 / Q000276:immunology* / Q000302:isolation & purification; D014407:Tumor Cells, Cultured; D014412:Tumor Virus Infections / Q000628:therapy*; D014611:Vaccination; D019444:Vaccines, DNA; D014614:Vaccines, Synthetic / Q000627:therapeutic use; D014765:Viral Vaccines / Q000627:therapeutic use*
D000952:Antigens, Polyomavirus Transforming; D018985:Epitopes, B-Lymphocyte; D011994:Recombinant Proteins; D019444:Vaccines, DNA; D014614:Vaccines, Synthetic; D014765:Viral Vaccines